Skip to main content

Koh Bong Y's Form 4 filing

KalVista Pharmaceuticals, Inc. (KALV) · filed Feb 1, 2024

Accession no.
0001415889-24-002183
Filed
Feb 1, 2024, 4:38 PM ET
Trade date
Jan 30, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market purchases total $1.27M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Koh Bong YCIK 000161597910% Owner
Shah Nimish PCIK 000169808210% Owner
Venrock Healthcare Capital Partners III, L.P.CIK 000173804810% Owner
VHCP Management III, LLCCIK 000173805310% Owner
VHCP Co-Investment Holdings III, LLCCIK 000175076110% Owner
Venrock Healthcare Capital Partners EG, L.P.CIK 000180851210% Owner
VHCP Management EG, LLCCIK 000180851810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 30, 2024Common StockPPurchaseAcquired+88,099$14.47F1+$1,274,792.534,738,683Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.25 to $14.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)